Anthony Buisson
YOU?
Author Swipe
View article: IMPACT OF ENDOMETRIOSIS ON THE PROGRESSION OF INFLAMMATORY BOWEL DISEASES: A MULTICENTER RETROSPECTIVE STUDY
IMPACT OF ENDOMETRIOSIS ON THE PROGRESSION OF INFLAMMATORY BOWEL DISEASES: A MULTICENTER RETROSPECTIVE STUDY Open
Introduction: Women with endometriosis have a higher risk of developing inflammatory bowel diseases (IBD). This study aimed to better understanding the impact of endometriosis on the course of IBD. Methods: We conducted a retrospective coh…
View article: Diet and clinical remission in patients with inflammatory bowel disease: A multicenter cross-sectional study
Diet and clinical remission in patients with inflammatory bowel disease: A multicenter cross-sectional study Open
CD remission was associated with higher intakes of fruits, coffee and a Mediterranean diet, while UC remission was associated with higher intakes of fruits and salad. As this was a cross-sectional study, the main limitation was the possibi…
View article: <b>Persistence mechanisms of Crohn's disease-associated adherent invasive</b> <i> <b>E</b> scherichia <b>coli</b> </i> <b>within macrophages</b>
<b>Persistence mechanisms of Crohn's disease-associated adherent invasive</b> <i> <b>E</b> scherichia <b>coli</b> </i> <b>within macrophages</b> Open
Patients with Crohn's disease exhibit abnormal intestinal colonization by Proteobacteria, particularly adherent-invasive Escherichia coli (AIEC). These bacteria predominate in the mucus, adhere to epithelial cells, colonize them, and survi…
View article: Knowledge and acceptability of the Lémann Index as a tool to measure disease progression and bowel damage in Crohn’s disease: results from an international survey
Knowledge and acceptability of the Lémann Index as a tool to measure disease progression and bowel damage in Crohn’s disease: results from an international survey Open
Background/Aims: Crohn’s disease (CD) progresses to structural bowel damage (SBD). The Lémann Index (LI) captures stricture extent/severity, penetrating disease and surgery as a SBD score, and is earmarked for future CD modification trials…
View article: Real-world comparison of effectiveness between ustekinumab and a second-line anti-TNF agent in patients with symptomatic stricturing Crohn’s disease failing to respond to a first-line anti-TNF agent: the USTEKNOSIS study
Real-world comparison of effectiveness between ustekinumab and a second-line anti-TNF agent in patients with symptomatic stricturing Crohn’s disease failing to respond to a first-line anti-TNF agent: the USTEKNOSIS study Open
Background: Anti-tumor necrosis factor (TNF) agents are now accepted as the first-line medical treatment for stricturing Crohn’s disease (CD). However, data are lacking about the effectiveness of advanced therapies after anti-TNF failure. …
View article: Systematic review and network meta-analysis comparing the efficacy of conventional therapy and biologics to prevent endoscopic postoperative recurrence in patients with Crohn’s disease
Systematic review and network meta-analysis comparing the efficacy of conventional therapy and biologics to prevent endoscopic postoperative recurrence in patients with Crohn’s disease Open
Background: As no direct comparison is available between drugs to prevent endoscopic postoperative recurrence (POR) in Crohn’s disease (CD), hierarchizing these therapeutic options remains challenging. Objectives: We aimed to compare the e…
View article: Blood proteomic signatures associated with disease activity in inflammatory bowel diseases
Blood proteomic signatures associated with disease activity in inflammatory bowel diseases Open
Background and Aims Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), remain heterogeneous disorders with variable response to biologics. Post-operative recurrence in CD is common despite surgery…
View article: Subcutaneous Infliximab for Perianal Crohn's Disease: The BioLap-Rem Multicenter Study From the GETAID
Subcutaneous Infliximab for Perianal Crohn's Disease: The BioLap-Rem Multicenter Study From the GETAID Open
INTRODUCTION: Intravenous infliximab (IFX) is the cornerstone for treating patients with perianal Crohn's disease (pCD). Data on the recently launched subcutaneous (SC) IFX for pCD are limited. The aim of our study was to evaluate the effe…
View article: Impact of dietary emulsifiers on the presence of adherent-invasive Escherichia coli in Crohn’s disease
Impact of dietary emulsifiers on the presence of adherent-invasive Escherichia coli in Crohn’s disease Open
Adherent-invasive Escherichia coli (AIEC) has been implicated in Crohn’s disease (CD) pathogenesis. We aimed to evaluate the impact of dietary factors on the presence of AIEC in patients with CD and to identify AIEC-associated mucosa…
View article: Patient and First‐Degree Relatives Perceptions About Prediction and Prevention of Inflammatory Bowel Disease—A Multinational Survey
Patient and First‐Degree Relatives Perceptions About Prediction and Prevention of Inflammatory Bowel Disease—A Multinational Survey Open
Background and Objective While significant advances have been made in identifying biomarkers for predicting inflammatory bowel disease (IBD) onset, little is known about the willingness of at‐risk individuals to undergo predictive testing …
View article: Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease
Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease Open
Goals: We assessed clinical outcomes over 6 months in an integrated analysis of inflammatory bowel disease (IBD) patients switching from intravenous (IV) to subcutaneous (SC) infliximab (IFX). Background: Real-world data from large multina…
View article: Efficacy of different modalities of faecal microbiota transplantation in ulcerative colitis: systematic review and network meta-analysis
Efficacy of different modalities of faecal microbiota transplantation in ulcerative colitis: systematic review and network meta-analysis Open
Background: While several small sample size randomized controlled trials suggested the superiority of faecal microbiota transplantation (FMT) over placebo in ulcerative colitis (UC), the most effective modality to perform FMT remains unkno…
View article: The CROCO (CROhn’s Disease COhort Study) – study design and protocol
The CROCO (CROhn’s Disease COhort Study) – study design and protocol Open
Background: Crohn’s disease (CD) is a chronic, relapsing and remitting inflammatory bowel disease that can be associated with significant bowel damage and disability. The Lémann Index (LI) is a validated tool for measuring cumulative bowel…
View article: Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitis
Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitis Open
Tofacitinib and upadacitinib appear to have similar effectiveness and safety profiles when used for the treatment of ASUC.
View article: The EXTENT Study: Results From an International Expert Delphi Consensus to Define Ultrasonographic Parameters for Measuring Bowel Damage in Crohn’s Disease
The EXTENT Study: Results From an International Expert Delphi Consensus to Define Ultrasonographic Parameters for Measuring Bowel Damage in Crohn’s Disease Open
This study supports intestinal ultrasonography as a promising tool for assessing bowel damage in Crohn's disease, providing an alternative to magnetic resonance imaging/computed tomography and colonoscopy. Implementing intestinal ultrasono…
View article: Efficacy and Safety of Infliximab and Vedolizumab Maintenance Therapy in Patients with Crohn’s Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis
Efficacy and Safety of Infliximab and Vedolizumab Maintenance Therapy in Patients with Crohn’s Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis Open
Background/Objectives: Direct comparative data for infliximab and vedolizumab are limited due to lack of head-to-head trials. This systematic review and meta-analysis compared the efficacy and safety of infliximab and vedolizumab as intrav…
View article: Effectiveness and Safety of a Second <scp>JAK</scp> Inhibitor in Ulcerative Colitis: The <scp>J2J</scp> Multicentre Study
Effectiveness and Safety of a Second <span>JAK</span> Inhibitor in Ulcerative Colitis: The <span>J2J</span> Multicentre Study Open
Background While three Janus kinase inhibitors (JAKi) have demonstrated efficacy in ulcerative colitis (UC), scarce data exist regarding JAKi intraclass switching. Aim To evaluate the effectiveness and safety of a second JAK inhibitor in U…
View article: Direct comparison of simultaneous and sequential endoscopic metallic bilateral stenting in malignant hilar biliary obstruction
Direct comparison of simultaneous and sequential endoscopic metallic bilateral stenting in malignant hilar biliary obstruction Open
BACKGROUND Endoscopic bilateral biliary drainage is a first line palliative treatment for unresectable malignant hilar biliary obstruction (MHBO) but remains technically challenging. The emergence of self-expandable metallic stents carried…
View article: A Risk Stratification Tool for Relapse After Intravenous-To-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel Diseases
A Risk Stratification Tool for Relapse After Intravenous-To-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel Diseases Open
INTRODUCTION: A subcutaneous formulation of infliximab was recently approved for maintenance therapy of inflammatory bowel disease (IBD). However, limited clinical experience, particularly with patients on escalated intravenous infliximab …
View article: Switching from intravenous to subcutaneous infliximab is safe and feasible in patients with perianal Crohn’s disease
Switching from intravenous to subcutaneous infliximab is safe and feasible in patients with perianal Crohn’s disease Open
Background and objectives: We assessed the evolution of perianal lesions after switching intravenous (IV) to subcutaneous (SC) infliximab in patients with Crohn’s disease (CD). Design: Subgroup analysis of REMSWITCH studies. Methods: We de…
View article: Effectiveness and Safety of Upadacitinib Induction Therapy for 223 Patients With Crohn's Disease: A <scp>GETAID</scp> Multicentre Cohort Study
Effectiveness and Safety of Upadacitinib Induction Therapy for 223 Patients With Crohn's Disease: A <span>GETAID</span> Multicentre Cohort Study Open
Background Real‐world effectiveness and safety of upadacitinib in patients with Crohn's disease (CD) remain unclear. Aims This study aimed to evaluate the effectiveness and safety of upadacitinib in a real‐world cohort. Methods From Septem…
View article: DOP087 Characterization of a European population with recently diagnosed Crohn’s Disease: results from the prospective Crohn´s Disease Cohort (CROCO) Study
DOP087 Characterization of a European population with recently diagnosed Crohn’s Disease: results from the prospective Crohn´s Disease Cohort (CROCO) Study Open
Background Crohn’s disease (CD) is a chronic and progressive condition with a growing global prevalence, leading to potential bowel damage and disability. Data on the clinical presentation, outcomes, and treatment options in newly diagnose…
View article: P0684 Real world experience with granulocyte and monocyte adsorptive apheresis (ADACOLUMN®) in patients with refractory inflammatory bowel disease: a retrospective observational multicenter cohort study
P0684 Real world experience with granulocyte and monocyte adsorptive apheresis (ADACOLUMN®) in patients with refractory inflammatory bowel disease: a retrospective observational multicenter cohort study Open
Background Granulocyte and monocyte adsorptive apheresis (GMA) with ADACOLUMN® (JIMRO Takasaki Japan) is an effective and safe therapeutic option for patients with mild to moderate inflammatory bowel disease (IBD) refractory to pharmacolog…
View article: P0418 The implementation of IBD-dedicated multidisciplinary healthcare pathway improves patients’ satisfaction and reduces disability in patients with IBD
P0418 The implementation of IBD-dedicated multidisciplinary healthcare pathway improves patients’ satisfaction and reduces disability in patients with IBD Open
Background The management of patients with Inflammatory Bowel Diseases (IBD) has recently evolved highlighting the need for holistic approach. We evaluated patients’ satisfaction after the implementation of an IBD-dedicated multidisciplina…
View article: DOP042 Bowel damage and its correlation with the disability index in patients with recently diagnosed Crohn´s disease
DOP042 Bowel damage and its correlation with the disability index in patients with recently diagnosed Crohn´s disease Open
Background Crohn’s disease (CD) progression manifests as bowel damage (BD) and disability; prevention of both is a long-term treatment target in CD. However, the longitudinal characterization of BD and disability in early CD patients remai…
View article: P0611 Effectiveness comparisons between tofacitinib, filgotinib and upadacitinib in ulcerative colitis: results from the JAKARTA real-world evidence multicenter study
P0611 Effectiveness comparisons between tofacitinib, filgotinib and upadacitinib in ulcerative colitis: results from the JAKARTA real-world evidence multicenter study Open
Background As no direct comparisons exist, we compared the effectiveness of tofacitinib (TOFA), filgotinib (FILGO) and upadacitinib (UPA) in patients with Ulcerative Colitis (UC). Methods In this retrospective multicenter study, we include…
View article: P0695 Quantifying the benefit-risk trade-offs adult patients and providers are willing to make when considering advanced therapies for moderate to severe Ulcerative Colitis: A discrete choice experiment
P0695 Quantifying the benefit-risk trade-offs adult patients and providers are willing to make when considering advanced therapies for moderate to severe Ulcerative Colitis: A discrete choice experiment Open
Background As advanced therapy options for ulcerative colitis (UC) increase, it is important to understand the benefit-risk trade-offs patients and providers are willing to make to better inform shared decision making. Methods We used a cr…
View article: P0654 Switching from intravenous to subcutaneous infliximab: physicians’ practice and patients’ satisfaction - Results from a nationwide transectional study
P0654 Switching from intravenous to subcutaneous infliximab: physicians’ practice and patients’ satisfaction - Results from a nationwide transectional study Open
Background Subcutaneous (SC) infliximab is efficient and safe in inflammatory bowel diseases (IBD), but no guidelines exist regarding practical modalities of switching from IV to SC infliximab. This study aimed to describe current practice…
View article: P0706 Dose intensification of subcutaneous vedolizumab is an effective and safe option in Inflammatory Bowel Disease patients: Results from the multicentre OPTI-VEDO study
P0706 Dose intensification of subcutaneous vedolizumab is an effective and safe option in Inflammatory Bowel Disease patients: Results from the multicentre OPTI-VEDO study Open
Background Subcutaneous (SC) vedolizumab (VDZ) has demonstrated its efficacy and safety in patients with moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD). This study aimed to evaluate the effectiveness and safety of SC V…